Home › Companies › Mineralys Therapeutics, Inc. › 2025-2026
At Mineralys Therapeutics, Inc.'s shareholder meeting held May 21, 2026, in the 2025-2026 proxy season, 73 asset managers reported how they voted on 4 ballot items in their SEC Form N-PX filings, covering 934 separate fund positions. On the most widely held item on that ballot — Election of Class III directors for a three-year term to expire at the 2029 annual meeting of… — FOR was 61% of the votes cast (FOR divided by FOR plus WITHHELD, because this ballot offered only for and withhold; abstentions, broker non-votes and unvoted shares are excluded because none of them took a side), which is more than half. Whether the item was approved is for the filing to say; that statement has not been read for this item. Source: Mineralys Therapeutics, Inc.'s Form 8-K, Item 5.07, filed with the U.S. Securities and Exchange Commission on May 22, 2026.
Download data (CSV): ballot items · votes by manager · column guide.
Compiled from SEC Form N-PX filings and Mineralys Therapeutics, Inc.’s Form 8-K, filed May 22, 2026 (Item 5.07 on EDGAR). Page generated November 8, 2026.
Meeting of May 21, 2026: 4 items on Mineralys Therapeutics, Inc.’s Form 8-K, filed May 22, 2026: 1 approved · 3 without a stated outcome.
Material dissent: a director nominee under 80% of the votes cast, say-on-pay under 70%, any other item the board put forward under 80%, or a shareholder proposal with more than 50%, on the company’s own Form 8-K tally. How this is decided
Proxy season: 2025-2026
Explore Mineralys Therapeutics, Inc. in the interactive database Compare manager voting policies
These tallies are Mineralys Therapeutics, Inc.’s own, as disclosed to the U.S. Securities and Exchange Commission on Form 8-K, filed May 22, 2026 (Item 5.07, “Submission of Matters to a Vote of Security Holders”). They cover every share voted at the meeting, not just the funds that file Form N-PX.
| Ballot item | For | Against | Abstain | Withheld | Broker non-votes | Support (of votes cast) | Reported outcome | Voting standard |
|---|---|---|---|---|---|---|---|---|
| Elect Director: Srinivas Akkaraju, M.D., Ph.D. | 40,667,555 | -- | -- | 26,447,538 | 5,569,960 | 61% | Not verified | — |
| Elect Director: Brian Taylor Slingsby, M.D., Ph.D., M.P.H. | 42,487,140 | -- | -- | 24,627,953 | 5,569,960 | 63% | Not verified | — |
| Elect Director: Daphne Karydas | 66,626,766 | -- | -- | 488,327 | 5,569,960 | 99.2% | Not verified | — |
| 2. To ratify the appointment of Ernst & Young LLP as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2026 | 72,648,272 | 9,516 | 27,265 | -- | 0 | 99.9% | Approved | — |
Source: Mineralys Therapeutics, Inc., Form 8-K, filed with the SEC on May 22, 2026 — read the filing on EDGAR.
Each item below shows how the 73 asset managers that disclosed a Mineralys Therapeutics, Inc. vote in their SEC Form N-PX filings actually voted. Share totals are the shares those managers' funds voted, summed across every fund they report.
Combines 4 wordings of this item as funds reported it.
61% Majority: yes · of votes cast
Description as filed by funds: Election of Class III directors for a three-year term to expire at the 2029 annual meeting of stockholders: Srinivas Akkaraju, M.D., Ph.D.
Mineralys Therapeutics, Inc.’s own tally for this item (“Elect Director: Srinivas Akkaraju, M.D., Ph.D.”): 40,667,555 for, 26,447,538 withheld, per its Form 8-K filed May 22, 2026 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.
Reported outcome: not verified — the filing’s own statement of the outcome could not be identified for this item.
Support: 61% of votes cast — FOR ÷ (FOR + WITHHELD); abstentions and broker non-votes are excluded.
Fund voting reports and institutional-manager reports both cover this item. An institutional manager can report shares that a fund it advises also reports, so the two are shown separately below and never added together, and their sum is not shown (fund and manager reports combined may count the same shares twice).
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Fidelity | 0 | 0 | 0 | 5,846,548 | Withhold |
| Vanguard | 1,866,626 | 0 | 36 | 3,115,247 | Mixed |
| BlackRock | 56,370 | 0 | 0 | 1,786,723 | Withhold |
| State Street | 1,728,424 | 0 | 0 | 2,090 | For |
| T. Rowe Price | 689,404 | 0 | 0 | 0 | For |
| American Century | 0 | 0 | 0 | 683,898 | Withhold |
| FRANKLIN STRATEGIC SERIES | 0 | 0 | 0 | 623,239 | Withhold |
| AllianceBernstein | 0 | 0 | 0 | 532,911 | Withhold |
| Prudential/PGIM | 495,196 | 0 | 0 | 0 | For |
| Charles Schwab | 443,799 | 0 | 0 | 0 | For |
| Capital Group | 398,179 | 0 | 0 | 0 | For |
| Hartford | 235,999 | 0 | 0 | 0 | For |
| Equitable | 40,539 | 0 | 0 | 108,107 | Mixed |
| Voya | 0 | 0 | 0 | 119,512 | Withhold |
| Pacific Life | 0 | 0 | 0 | 112,154 | Withhold |
| Principal | 0 | 0 | 0 | 111,491 | Withhold |
| TIAA | 0 | 0 | 0 | 107,246 | Withhold |
| Russell Investments | 0 | 0 | 0 | 96,936 | Withhold |
| Brighthouse | 46,961 | 0 | 0 | 40,553 | Mixed |
| Lord Abbett | 86,061 | 0 | 0 | 0 | For |
| AIG/SunAmerica | 0 | 0 | 0 | 84,758 | Withhold |
| QUANTITATIVE MASTER SERIES LLC | 0 | 0 | 0 | 76,562 | Withhold |
| Dimensional | 0 | 0 | 0 | 70,697 | Withhold |
| Putnam | 37,425 | 0 | 0 | 32,762 | Mixed |
| ALPS ETF Trust | 0 | 0 | 0 | 65,695 | Withhold |
Fund voting reports, all 71 managers: 6,439,822 for, 13,982,409 withheld, 36 abstained. Showing the 25 largest; every one is in the interactive database (link above).
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Catalys Pacific, LLC | 7,903,838 | 0 | 0 | 0 | For |
| Eleva Capital SAS | 0 | 0 | 0 | 15,746 | Withhold |
Institutional-manager reports, all 2 managers: 7,903,838 for, 15,746 withheld.
Combines 3 wordings of this item as funds reported it.
63% Majority: yes · of votes cast
Description as filed by funds: Election of Class III directors for a three-year term to expire at the 2029 annual meeting of stockholders: Brian Taylor Slingsby, M.D., Ph.D., M.P.H.
Mineralys Therapeutics, Inc.’s own tally for this item (“Elect Director: Brian Taylor Slingsby, M.D., Ph.D., M.P.H.”): 42,487,140 for, 24,627,953 withheld, per its Form 8-K filed May 22, 2026 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.
Reported outcome: not verified — the filing’s own statement of the outcome could not be identified for this item.
Support: 63% of votes cast — FOR ÷ (FOR + WITHHELD); abstentions and broker non-votes are excluded.
The 72 asset managers below reported 8,628,827 for, 11,809,152 withheld, 33 abstained.
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Fidelity | 1,099,924 | 0 | 0 | 4,746,624 | Mixed |
| Vanguard | 4,979,690 | 0 | 33 | 2,185 | For |
| BlackRock | 0 | 0 | 0 | 1,843,093 | Withhold |
| State Street | 3,512 | 0 | 0 | 1,727,002 | Withhold |
| T. Rowe Price | 0 | 0 | 0 | 689,404 | Withhold |
| American Century | 0 | 0 | 0 | 683,898 | Withhold |
| FRANKLIN STRATEGIC SERIES | 0 | 0 | 0 | 623,239 | Withhold |
| AllianceBernstein | 532,911 | 0 | 0 | 0 | For |
| Prudential/PGIM | 421,311 | 0 | 0 | 73,885 | Mixed |
| Charles Schwab | 443,799 | 0 | 0 | 0 | For |
| Capital Group | 398,179 | 0 | 0 | 0 | For |
| Hartford | 235,999 | 0 | 0 | 0 | For |
| Equitable | 31,050 | 0 | 0 | 117,596 | Mixed |
| Voya | 0 | 0 | 0 | 119,512 | Withhold |
| Pacific Life | 95,915 | 0 | 0 | 16,239 | Mixed |
| Principal | 107,637 | 0 | 0 | 3,854 | For |
| TIAA | 0 | 0 | 0 | 107,246 | Withhold |
| Russell Investments | 0 | 0 | 0 | 96,936 | Withhold |
| Brighthouse | 0 | 0 | 0 | 87,514 | Withhold |
| Lord Abbett | 0 | 0 | 0 | 86,061 | Withhold |
| AIG/SunAmerica | 0 | 0 | 0 | 84,758 | Withhold |
| QUANTITATIVE MASTER SERIES LLC | 0 | 0 | 0 | 76,562 | Withhold |
| Dimensional | 0 | 0 | 0 | 70,697 | Withhold |
| Putnam | 37,425 | 0 | 0 | 32,762 | Mixed |
| ALPS ETF Trust | 0 | 0 | 0 | 65,695 | Withhold |
Showing the 25 largest of 72 asset managers. All 72 are in the interactive database (link above).
Combines 3 wordings of this item as funds reported it.
99.2% Majority: yes · of votes cast
Description as filed by funds: Election of Class III directors for a three-year term to expire at the 2029 annual meeting of stockholders: Daphne Karydas
Mineralys Therapeutics, Inc.’s own tally for this item (“Elect Director: Daphne Karydas”): 66,626,766 for, 488,327 withheld, per its Form 8-K filed May 22, 2026 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.
Reported outcome: not verified — the filing’s own statement of the outcome could not be identified for this item.
Support: 99.2% of votes cast — FOR ÷ (FOR + WITHHELD); abstentions and broker non-votes are excluded.
The 72 asset managers below reported 20,340,781 for, 97,230 withheld, 1 abstained.
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Fidelity | 5,846,548 | 0 | 0 | 0 | For |
| Vanguard | 4,979,722 | 0 | 1 | 2,185 | For |
| BlackRock | 1,843,093 | 0 | 0 | 0 | For |
| State Street | 1,730,514 | 0 | 0 | 0 | For |
| T. Rowe Price | 689,404 | 0 | 0 | 0 | For |
| American Century | 683,898 | 0 | 0 | 0 | For |
| FRANKLIN STRATEGIC SERIES | 623,239 | 0 | 0 | 0 | For |
| AllianceBernstein | 532,911 | 0 | 0 | 0 | For |
| Prudential/PGIM | 495,196 | 0 | 0 | 0 | For |
| Charles Schwab | 443,799 | 0 | 0 | 0 | For |
| Capital Group | 398,179 | 0 | 0 | 0 | For |
| Hartford | 235,999 | 0 | 0 | 0 | For |
| Equitable | 148,646 | 0 | 0 | 0 | For |
| Voya | 119,512 | 0 | 0 | 0 | For |
| Pacific Life | 112,154 | 0 | 0 | 0 | For |
| Principal | 111,491 | 0 | 0 | 0 | For |
| TIAA | 107,246 | 0 | 0 | 0 | For |
| Russell Investments | 96,936 | 0 | 0 | 0 | For |
| Brighthouse | 63,166 | 0 | 0 | 24,348 | Mixed |
| Lord Abbett | 86,061 | 0 | 0 | 0 | For |
| AIG/SunAmerica | 84,758 | 0 | 0 | 0 | For |
| QUANTITATIVE MASTER SERIES LLC | 76,562 | 0 | 0 | 0 | For |
| Dimensional | 0 | 0 | 0 | 70,697 | Withhold |
| Putnam | 70,187 | 0 | 0 | 0 | For |
| ALPS ETF Trust | 65,695 | 0 | 0 | 0 | For |
Showing the 25 largest of 72 asset managers. All 72 are in the interactive database (link above).
Combines 2 wordings of this item as funds reported it.
99.9% Approved · of votes cast
Description as filed by funds: RATIFY THE APPOINTMENT OF ERNST & YOUNG LLP AS MINERALYS THERAPEUTICS, INC.'S INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM FOR THE FISCAL YEAR ENDING DECEMBER 31, 2026.
Mineralys Therapeutics, Inc.’s own tally for this item (“2. To ratify the appointment of Ernst & Young LLP as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2026”): 72,648,272 for, 9,516 against — passed, per its Form 8-K filed May 22, 2026 (Item 5.07).
Reported outcome: Approved, in the filing’s own words: “Proposal 2: To ratify the appointment of Ernst & Young LLP as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2026.”
Support: 99.9% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.
The 72 asset managers below reported 20,413,664 for, 24,348 abstained.
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Fidelity | 5,846,548 | 0 | 0 | 0 | For |
| Vanguard | 4,981,908 | 0 | 0 | 0 | For |
| BlackRock | 1,843,093 | 0 | 0 | 0 | For |
| State Street | 1,730,514 | 0 | 0 | 0 | For |
| T. Rowe Price | 689,404 | 0 | 0 | 0 | For |
| American Century | 683,898 | 0 | 0 | 0 | For |
| FRANKLIN STRATEGIC SERIES | 623,239 | 0 | 0 | 0 | For |
| AllianceBernstein | 532,911 | 0 | 0 | 0 | For |
| Prudential/PGIM | 495,196 | 0 | 0 | 0 | For |
| Charles Schwab | 443,799 | 0 | 0 | 0 | For |
| Capital Group | 398,179 | 0 | 0 | 0 | For |
| Hartford | 235,999 | 0 | 0 | 0 | For |
| Equitable | 148,646 | 0 | 0 | 0 | For |
| Voya | 119,512 | 0 | 0 | 0 | For |
| Pacific Life | 112,154 | 0 | 0 | 0 | For |
| Principal | 111,491 | 0 | 0 | 0 | For |
| TIAA | 107,246 | 0 | 0 | 0 | For |
| Russell Investments | 96,936 | 0 | 0 | 0 | For |
| Brighthouse | 63,166 | 0 | 24,348 | 0 | Mixed |
| Lord Abbett | 86,061 | 0 | 0 | 0 | For |
| AIG/SunAmerica | 84,758 | 0 | 0 | 0 | For |
| QUANTITATIVE MASTER SERIES LLC | 76,562 | 0 | 0 | 0 | For |
| Dimensional | 70,697 | 0 | 0 | 0 | For |
| Putnam | 70,187 | 0 | 0 | 0 | For |
| ALPS ETF Trust | 65,695 | 0 | 0 | 0 | For |
Showing the 25 largest of 72 asset managers. All 72 are in the interactive database (link above).
Ranked separately for each type of Form N-PX report. An institutional manager can report shares that a fund it advises also reports, so the two tables can list the same shares and are never added together. Each is ranked by the shares voted on the item that the most managers of that type reported, shown as a share of the 82,498,101 shares outstanding at the time of that meeting.
| # | Asset manager | % of shares outstanding |
|---|---|---|
| 1 | Fidelity | 7.09% |
| 2 | Vanguard | 6.04% |
| 3 | BlackRock | 2.23% |
| 4 | State Street | 2.10% |
| 5 | T. Rowe Price | 0.84% |
| 6 | American Century | 0.83% |
| 7 | FRANKLIN STRATEGIC SERIES | 0.76% |
| 8 | AllianceBernstein | 0.65% |
| 9 | Prudential/PGIM | 0.60% |
| 10 | Charles Schwab | 0.54% |
| # | Asset manager | % of shares outstanding |
|---|---|---|
| 1 | Catalys Pacific, LLC | 9.58% |
| 2 | Eleva Capital SAS | 0.02% |
As disclosed to the SEC in Form 13F (quarter-end holdings of 30 large managers), Schedules 13D and 13G (beneficial ownership above 5%) and the company’s own proxy statement (DEF 14A). Each row names its form.
| Holder | % outstanding | Disclosure |
|---|---|---|
| Brian Taylor Slingsby, M.D., Ph.D., M.P.H. | 9.70% | DEF14A |
| Catalys Pacific Fund, LP | 9.70% | 13G |
| Entities affiliated with RA Capital Management, L.P. | 9.67% | DEF14A |
| Srinivas Akkaraju, M.D., Ph.D. | 7.24% | DEF14A |
| Samsara BioCapital, L.P. | 7.12% | DEF14A |
| FMR (Fidelity) | 5.89% | 13F |
| BlackRock | 5.43% | 13F |
| FMR LLC | 5.41% | 13G |
| Wellington Management | 4.07% | 13F |
| Vanguard Group | 4.06% | 13F |
Percentages above are of 82,498,101 shares outstanding, as reported by Mineralys Therapeutics, Inc. on its Form 10-Q dated April 27, 2026 (see the filing on EDGAR). This is the count contemporaneous with the 2025-2026 meeting, not today’s. Each holding is as of its own filing, which may be dated before or after the meeting.
Every figure above is derived from filings made with the US Securities and Exchange Commission: Form N-PX, in which registered funds disclose how they voted every proxy and institutional managers disclose their votes on executive pay (say-on-pay, say-on-frequency and golden parachutes), and Form 8-K Item 5.07, in which the company reports its own meeting results. Shares outstanding are taken from Mineralys Therapeutics, Inc.’s 10-Q dated April 27, 2026. This page is a static snapshot rebuilt weekly on November 8, 2026; a live search always shows the current data.
Mineralys Therapeutics, Inc. proxy season coverage: 2025-2026 (this page).
proxyvotesnow.com, “Mineralys Therapeutics (MLYS) 2026 Annual Meeting: Vote Results”, https://proxyvotesnow.com/company/mineralys-therapeutics-inc/2026 (version of November 9, 2026). Derived from SEC Form N-PX and Form 8-K filings; tables licensed CC BY 4.0. Licence: CC BY 4.0.